Detail of the clinical trial

Title of the trial A phase III multi-center, open label, randomised study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)
EudraCT number 2007-000208-34
Protocol number CAMN107A2303
Sponsor Novartis Pharma Services Switzerland
Indications Hemato-oncology
Diagnosis chronic myelogenous leukemia
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Male
Female
Patients
Year of receiving the request to Institute (SÚKL) 2007
Date of approval by Institute (SÚKL) 20.4.2007
Date of approval by EC 10.3.2008
Date of initiation CT in ČR 10.12.2007
Date of ending CT in ČR 13.12.2018
Notice
Sites ÚHKT, U nemocnice 1, Praha 2
hematologická klinika, FN Olomouc

‹‹ Back to list